SEC Company Response from Oncotelic Therapeutics, (OTLC) — Dec 22, 2025

Oncotelic Therapeutics, Inc.
Date: Dec. 22, 2025 · CIK: 0000908259 · Accession: 0001493152-25-028826

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-291724

Date

December 23, 2025

Author

Oncotelic Therapeutics

Form

CORRESP

Company

Oncotelic Therapeutics, Inc.

Letter

Re: Oncotelic Therapeutics, Inc.

December 22, 2025

VIA EDGAR

Securities and Exchange Commission,

F Street N.E.

Washington, DC 20549

Attn: Doris Gana

Registration Statement on Form S-1

File No. 333-291724

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oncotelic Therapeutics, Inc, a Delaware corporation hereby respectfully requests that the effectiveness of the above-referenced Registration Statement on Form S-1 be accelerated to 4:00 p.m. Eastern Time on Tuesday, December 23, 2025, or as soon thereafter as practicable.

Sincerely,
Oncotelic Therapeutics,
Inc.

Show Raw Text

CORRESP
 1
 filename1.htm

 December
22, 2025

 VIA
EDGAR

 Securities
and Exchange Commission,

 100
F Street N.E.

 Washington,
DC 20549

 Attn:
Doris Gana

 Re:
 Oncotelic Therapeutics,
 Inc.

 Registration Statement
 on Form S-1

 File No. 333-291724

 Ladies
and Gentlemen:

 Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Oncotelic Therapeutics, Inc, a Delaware corporation hereby respectfully requests
that the effectiveness of the above-referenced Registration Statement on Form S-1 be accelerated to 4:00 p.m. Eastern Time on Tuesday,
December 23, 2025, or as soon thereafter as practicable.

 Sincerely,

 Oncotelic Therapeutics,
 Inc.

 By
 /s/
 Vuong Trieu

 Vuong Trieu

 Chief Executive Officer

SecProbe.io